These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838 [TBL] [Abstract][Full Text] [Related]
24. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation. Barkholt L; Linde A; Falk KI Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864 [TBL] [Abstract][Full Text] [Related]
25. [Remission of severe disease induced by CMV and lymphoproliferative post-transplant disease after changing the immunosuppressive regime]. Gómez E; Melón S; Fresno MF; Tricas L; Navascués R; de Oña M; Herreros M; Alvarez Grande J Nefrologia; 2002; 22(6):574-81. PubMed ID: 12516292 [TBL] [Abstract][Full Text] [Related]
26. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581 [TBL] [Abstract][Full Text] [Related]
27. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965 [TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076 [TBL] [Abstract][Full Text] [Related]
31. Associations of serum EBV DNA and gammopathy with post-transplant lymphoproliferative disease. Rosselet A; Vu DH; Meylan P; Chaubert AS; Schapira M; Pascual M; Aubert V; Tissot JD; Duchosal MA Clin Transplant; 2009; 23(1):74-82. PubMed ID: 19200218 [TBL] [Abstract][Full Text] [Related]
32. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046 [TBL] [Abstract][Full Text] [Related]
33. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? Burra P; Buda A; Livi U; Rigotti P; Zanus G; Calabrese F; Caforio A; Menin C; Canova D; Farinati F; Luciana Aversa SM Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1065-70. PubMed ID: 16957512 [TBL] [Abstract][Full Text] [Related]
34. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder. Purighalla R; Shapiro R; Jordan ML; Scantlebury VP; Gritsch HA; Vivas C; Randhawa PS Clin Transplant; 1997 Dec; 11(6):574-6. PubMed ID: 9408687 [TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes. Bräuninger A; Spieker T; Mottok A; Baur AS; Küppers R; Hansmann ML Eur J Immunol; 2003 Jun; 33(6):1593-602. PubMed ID: 12778477 [TBL] [Abstract][Full Text] [Related]
36. Lymphoproliferative disorders after renal transplantation along 2 decades: a large longitudinal study of 21.546 recipients. Franco A; Hernandez D; Zarraga S; Fructuoso AS; Crespo M; Mazuecos A; Corte CD; Benot AR; Ruiz JC; Beneyto I; Nefrologia (Engl Ed); 2023; 43(4):427-434. PubMed ID: 37813738 [TBL] [Abstract][Full Text] [Related]
37. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S; Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985 [TBL] [Abstract][Full Text] [Related]
38. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054 [TBL] [Abstract][Full Text] [Related]
39. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720 [TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus in pediatric patients after renal transplantation. Schwab M; Böswald M; Korn K; Ruder H Clin Nephrol; 2000 Feb; 53(2):132-9. PubMed ID: 10711415 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]